bioAffinity Technologies (NASDAQ:BIAF) announced on March 10, 2026, the launch of a large longitudinal clinical study involving 2,000 patients to evaluate the performance of its CyPath® Lung ...
NeXT Personal identifies circulating tumor DNA in 81% of early-stage lung adenocarcinoma cases, offering potential for better disease stratification and outcome prediction. Study: Ultrasensitive ctDNA ...
【Backgrounds】 In 2015, the First Affiliated Hospital of Guangzhou Medical University, in collaboration with the Guangdong Hetaoxiang Medical Charity Foundation and the Guangzhou Charity Association, ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results